$2.50 0.4%
ESPR Stock Price vs. AI Score (Last 150 days)
Data gathered: July 16

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Esperion Therapeutics

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.


Esperion Therapeutics
Price $2.50
Target Price Sign up
Volume 4,920,000
Market Cap $475M
Year Range $0.88 - $3.24
Dividend Yield 0%
Revenue per Employee $859,935
Industry Drug Manufacturers

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '24124M42M82M61M72M0.340
Q4 '2317M45M-28M-56M-42M-0.500
Q3 '2319M33M-14M-41M-28M-0.370
Q2 '2311M34M-23M-50M-37M-0.460
Q1 '239.9M30M-20M-62M-47M-0.790

Insider Transactions View All

Warren Eric filed to sell 165,586 shares at $2.9.
June 20 '24
Foody Joanne M. filed to sell 273,779 shares at $2.9.
June 20 '24
Warren Eric filed to sell 168,126 shares at $2.5.
May 20 '24
Warren Eric filed to sell 68,318 shares at $1.2.
September 21 '23
Warren Eric filed to sell 69,060 shares at $1.4.
August 21 '23

What is the Market Cap of Esperion Therapeutics?

The Market Cap of Esperion Therapeutics is $475M.

How Many People Work at Esperion Therapeutics?

As of our latest update, Esperion Therapeutics employed approximately 199 people worldwide. However, it's important to note that Esperion Therapeutics' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Esperion Therapeutics' revenue per employee?

$859,935. To calculate Esperion Therapeutics' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Esperion Therapeutics?

Currently, the price of one share of Esperion Therapeutics stock is $2.50.

How can I analyze the ESPR stock price chart for investment decisions?

The ESPR stock price chart above provides a comprehensive visual representation of Esperion Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Esperion Therapeutics shares. Our platform offers an up-to-date ESPR stock price chart, along with technical data analysis and alternative data insights.

Does ESPR offer dividends to its shareholders?

As of our latest update, Esperion Therapeutics (ESPR) does not offer dividends to its shareholders. Investors interested in Esperion Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Esperion Therapeutics?

Some of the similar stocks of Esperion Therapeutics are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.